AstraZeneca and insitro Announce AI Drug Discovery Deal Valued at Up to $1.5 Billion

AstraZeneca and insitro announced an AI-assisted drug discovery and licensing deal worth up to $1.5 billion on Oct. 15, with plans to identify drug targets and advance them together.

insitro is a California-based biotech, while AstraZeneca is an Anglo-Swedish drugmaker.

A separate South San Francisco AI lab project from Eli Lilly and NVIDIA involves planned investment of up to $1 billion over five years for drug discovery, manufacturing and related work.